Abcam, ab52917, Anti-VEGFA antibody [EP1176Y] - C-terminal

Size: 20µL / 100µL / 1mL
Anti-VEGFA antibody [EP1176Y] - C-terminal (ab52917) is a rabbit monoclonal antibody detecting VEGFA in Flow Cytometry (Intra), Flow Cytometry, IHC-P, ICC/IF . Suitable for Human, Mouse . - Biophysical QC for unrivalled batch-batch consistency - Over 220 publications - Trusted since 2007
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP1176Y,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human,
Applications:ICC/IF, Flow Cyt (Intra), IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:We do not guarantee IHC-P for mouse.This antibody fails to detect endogenous natural samples in WB. We recommend to use ab214424 for WB.

Product details:
Abcam recommended secondaries - Goat Anti-Rabbit HRP (
ab205718
) and Goat Anti-Rabbit Alexa Fluor® 488 (
ab150077
). Or search our wide range of secondary antibodies for use with your experiment.
Product Specifications
Anti-VEGFA antibody [EP1176Y] - C-terminal (ab52917) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P in human, mouse samples.
Anti-VEGFA antibody [EP1176Y] - C-terminal (ab52917) specifically detects VEGFA (UniProt ID: P15692; Molecular weight: 44kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL).
Quality and Validation
Abcam's high quality manufacturing and validation processes ensure Anti-VEGFA antibody [EP1176Y] - C-terminal (ab52917) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-VEGFA antibody [EP1176Y] - C-terminal (ab52917) has been cited over 221 times in peer reviewed journals and is trusted by the scientific community.
Anti-VEGFA antibody [EP1176Y] - C-terminal (ab52917) has 9 independent reviews from customers.
Related Products
Conjugation-ready, carrier free format available for antibody clone EP1176Y -
ab212816
Antibody clone EP1176Y is also available pre-conjugated to a variety of labels for your convenience - Biotin, Alexa Fluor® 488, Alexa Fluor® 647, Alexa Fluor® 594, PE (
ab195902
ab206886
ab206887
ab206888
ab209439
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Vascular endothelial growth factor A (VEGFA) also known as VEGF or vascular permeability factor (VPF) is a protein that plays a central role in angiogenesis as well as in the growth of blood vessels. The molecular weight of VEGFA varies depending on the isoform typically ranging from 34 to 42 kDa. VEGFA is expressed in many tissues including fibroblasts macrophages endothelial cells and platelets. Its expression levels can increase in response to stimuli like hypoxia or inflammatory cytokines. VEGFA is an important target in research for therapies related to vascular diseases and cancer.
Biological function summary
VEGFA functions by promoting the proliferation and migration of vascular endothelial cells. It operates both as a homodimer and as part of complex signaling cascades interacting with VEGF receptors on cell surfaces to trigger downstream signals for angiogenesis. This includes endothelial cell growth migration and the new blood vessel formation process. VEGFA's activity is important for physiological processes such as wound healing and embryonic development and it also contributes to pathological conditions through its unregulated expression in diseases.
Pathways
Many processes involve VEGFA including the PI3K/AKT pathway and the MAPK/ERK pathway. These pathways regulate cell survival growth and differentiation. Other proteins like PLGF (placenta growth factor) and VEGFB often accompany VEGFA in these pathways aiding in distinct but overlapping roles. These interactions are transmitted through binding to VEGF receptors such as VEGFR-1 and VEGFR-2 subsequently activating various signaling cascades necessary for cellular and tissue homeostasis.
VEGFA relates to cancer and age-related macular degeneration among others. In cancer overexpression of VEGFA can lead to excessive angiogenesis supplying blood to tumors and facilitating tumor growth. In age-related macular degeneration upregulation of VEGFA contributes to the progression of the disease by promoting the formation of abnormal blood vessels under the retina. Anti-VEGFA therapies such as anti-VEGF antibodies (e.g. bevacizumab) can target these overexpressed pathways. VEGFA interacts with other proteins like HIF-1α which regulates its expression under hypoxia a common condition in tumors.